PL2283844T3 - Stała farmaceutyczna formulacja leku zawierająca lopinawir - Google Patents

Stała farmaceutyczna formulacja leku zawierająca lopinawir

Info

Publication number
PL2283844T3
PL2283844T3 PL10184860T PL10184860T PL2283844T3 PL 2283844 T3 PL2283844 T3 PL 2283844T3 PL 10184860 T PL10184860 T PL 10184860T PL 10184860 T PL10184860 T PL 10184860T PL 2283844 T3 PL2283844 T3 PL 2283844T3
Authority
PL
Poland
Prior art keywords
lopinavir
pharmaceutical dosage
solid pharmaceutical
dosage formulation
formulation
Prior art date
Application number
PL10184860T
Other languages
English (en)
Inventor
Jörg Rosenberg
Ulrich Reinhold
Bernd Liepold
Gunther Berndl
Laman Alani
Soumojeet Ghosh
Jörg Breitenbach
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36678380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2283844(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of PL2283844T3 publication Critical patent/PL2283844T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
PL10184860T 2005-02-23 2006-02-21 Stała farmaceutyczna formulacja leku zawierająca lopinawir PL2283844T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/064,467 US8377952B2 (en) 2003-08-28 2005-02-23 Solid pharmaceutical dosage formulation
PCT/US2006/005944 WO2006091529A2 (en) 2005-02-23 2006-02-21 A solid pharmaceutical dosage formulation
EP06735552A EP1855683A2 (en) 2005-02-23 2006-02-21 A solid pharmaceutical dosage formulation
EP10184860.4A EP2283844B1 (en) 2005-02-23 2006-02-21 A solid pharmaceutical dosage formulation comprising lopinavir
EP10159672.4A EP2206500B1 (en) 2005-02-23 2006-02-21 A solid pharmaceutical dosage formulation comprising lopinavir

Publications (1)

Publication Number Publication Date
PL2283844T3 true PL2283844T3 (pl) 2019-03-29

Family

ID=36678380

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10184860T PL2283844T3 (pl) 2005-02-23 2006-02-21 Stała farmaceutyczna formulacja leku zawierająca lopinawir
PL10159672T PL2206500T3 (pl) 2005-02-23 2006-02-21 Stała farmaceutyczna formulacja leku zawierająca lopinawir

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10159672T PL2206500T3 (pl) 2005-02-23 2006-02-21 Stała farmaceutyczna formulacja leku zawierająca lopinawir

Country Status (38)

Country Link
US (3) US8377952B2 (pl)
EP (4) EP2206500B1 (pl)
JP (1) JP5087409B2 (pl)
KR (1) KR101429024B1 (pl)
CN (1) CN101163479B (pl)
AR (2) AR055734A1 (pl)
AU (1) AU2006216856B2 (pl)
BR (2) BR122012031169A2 (pl)
CA (2) CA2821046C (pl)
CL (3) CL2009001844A1 (pl)
CR (1) CR9353A (pl)
CY (2) CY1120377T1 (pl)
DK (2) DK2283844T3 (pl)
DO (2) DOP2006000050A (pl)
EA (1) EA014446B1 (pl)
ES (2) ES2694073T3 (pl)
GE (1) GEP20105083B (pl)
GT (2) GT200600295A (pl)
HR (2) HRP20180999T1 (pl)
HU (2) HUE041591T2 (pl)
IL (1) IL185390A (pl)
LT (2) LT2206500T (pl)
MX (1) MX2007010275A (pl)
MY (1) MY146247A (pl)
NO (1) NO20074807L (pl)
NZ (2) NZ560829A (pl)
PE (2) PE20061016A1 (pl)
PL (2) PL2283844T3 (pl)
PT (2) PT2283844T (pl)
RS (2) RS57938B1 (pl)
SI (2) SI2283844T1 (pl)
SV (1) SV2007002427A (pl)
TR (2) TR201809084T4 (pl)
TW (1) TWI381840B (pl)
UA (1) UA89220C2 (pl)
UY (2) UY29391A1 (pl)
WO (1) WO2006091529A2 (pl)
ZA (1) ZA200707022B (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
CA2568378C (en) * 2004-05-28 2013-03-19 Abbott Gmbh & Co. Kg Formulation obtained from a powder mixture comprising an inorganic pigment
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
US10532028B2 (en) * 2005-07-28 2020-01-14 Isp Investments Llc Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
CL2007002331A1 (es) * 2006-08-10 2008-04-18 Cipla Ltd Composicion oral solida que comprede uno o mas farmacos antirretrovirales y al menos un polimero insoluble en agua, en relacion aproximadamente 1:1 hasta 1:6; proceso de elaboracion; y uso para el tratamiento del vih.
US20090281132A1 (en) * 2006-09-04 2009-11-12 Kiran Kumar Narsaiah Velaveni Pharmaceutical formulation for use in hiv therapy
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
WO2008067164A2 (en) * 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
WO2008092057A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Formulation process method to produce spray dried products
US20100303901A1 (en) * 2007-04-26 2010-12-02 Eyal Shimoni Oral delivery of proteins and peptides
EP2188265A1 (en) * 2007-08-07 2010-05-26 Ranbaxy Laboratories Limited Process for preparation of amorphous lopinavir
US20100285115A1 (en) * 2007-10-29 2010-11-11 Cipla Limited Novel Antiretroviral Combination
WO2009084036A2 (en) * 2007-12-20 2009-07-09 Matrix Laboratories Limited Composition for treatment of viral infections
PA8809601A1 (es) * 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
EP3272337A3 (en) * 2008-02-28 2018-02-14 AbbVie Inc. Tablets
US20100222315A1 (en) * 2008-09-24 2010-09-02 Harbor BioSciencs, Inc. Patient populations and treatment methods
TWI471321B (zh) 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
WO2011013110A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
US20110034489A1 (en) 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors
US20130195978A1 (en) * 2010-05-10 2013-08-01 Hetero Research Foundation Darunavir Compositions
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP2564832A1 (en) * 2011-08-29 2013-03-06 Hexal AG Solid dosage form of HIV protease inhibitors
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
JP6314131B2 (ja) * 2012-05-03 2018-04-18 シプラ・リミテッド 抗レトロウイルス組成物
CN103655571B (zh) * 2012-09-11 2016-04-20 上海星泰医药科技有限公司 一种洛匹那韦和利托那韦复方高均匀度纳米共分散体及其制备方法
US20140234415A1 (en) * 2013-02-20 2014-08-21 Abbvie Inc. Tablet Dosage Forms
US10034865B2 (en) 2015-09-10 2018-07-31 Kashiv Pharma, Llc Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
CN108186578A (zh) * 2018-03-27 2018-06-22 聊城大学 一种利托那韦固体分散体的制备方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
EA202191371A1 (ru) * 2018-12-14 2021-12-27 Фуджифилм Корпорэйшн Фармацевтическая композиция и способ ее получения
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions
CN112263554B (zh) * 2020-10-22 2022-09-30 安徽贝克生物制药有限公司 一种洛匹那韦利托那韦复方片剂及其制备方法

Family Cites Families (405)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE973095C (de) 1955-01-19 1959-12-03 Kalle & Co Ag Verfahren zur UEberfuehrung von OElen in streufaehige Pulver durch Spruehtrocknung von OEl-in-Wasser-Emulsionen
HU176101B (en) 1977-12-29 1980-12-28 Gyogyszerkutato Intezet Process for producing bis-bracket-nitrozo-ureido-bracket closed-polyol derivatives
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
FR2525108B1 (fr) 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
JPS61205208A (ja) 1985-03-08 1986-09-11 Yamanouchi Pharmaceut Co Ltd 難溶性医薬品の速溶性製剤
US4590065A (en) 1985-04-18 1986-05-20 Colgate-Palmolive Company Stable flavor-containing dentifrice
US4758427A (en) 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
PH22025A (en) 1985-08-19 1988-05-13 Johnson & Son Inc S C Aqueous pyrethroid insecticidal formulations and method of increasing the stability thereof
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
ATE68704T1 (de) * 1986-12-18 1991-11-15 Bauer Kurt Heinz Gegenueber lichteinfluss stabilisiertes nifedipin- konzentrat und verfahren zu seiner herstellung.
US4804699A (en) * 1987-05-15 1989-02-14 Ici Americas Inc. Monomeric and oligomeric glutarate-based light stabilizers for plastics
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
WO1989005138A1 (en) 1987-12-08 1989-06-15 Mark Chasin Method of forming bioerodible implants for improved controlled drug release
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5368864A (en) 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
GB8903328D0 (en) 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
HU204529B (en) 1989-08-10 1992-01-28 Richter Gedeon Vegyeszet Process for producing new 1-oxa-2-oxo-8-aza-spiro(4,5)decane derivatives and pharmaceutical compositions containing them
US5075291A (en) 1989-11-22 1991-12-24 Ici Americas Inc. Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound
JPH07501259A (ja) 1990-06-01 1995-02-09 リサーチ　コーポレイション　テクノロジーズ，インコーポレイテッド 自己乳化型ガラス
SE9003296L (sv) 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
KR0166096B1 (ko) 1990-11-28 1999-01-15 우에하라 아키라 6-0-메틸에리쓰로마이신 a 유도체
ATE159426T1 (de) 1991-04-16 1997-11-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer festen dispersion
WO1993007859A1 (en) 1991-10-23 1993-04-29 Warner-Lambert Company Novel pharmaceutical pellets and process for their production
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
DK0617612T3 (da) * 1991-12-18 1998-04-14 Warner Lambert Co Fremgangsmåde til fremstilling af en fast dispersion
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
DE4201179A1 (de) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
EP0626850B1 (en) 1992-02-18 2002-05-15 Pharmos Corporation Dry compositions for preparing submicron emulsions
US5654003A (en) 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
ZA932268B (en) 1992-03-30 1993-11-11 Alza Corp Polymer system containing a partially soluble compound
CA2095776C (en) 1992-05-12 2007-07-10 Richard C. Fuisz Rapidly dispersable compositions containing polydextrose
IT1256026B (it) 1992-06-12 1995-11-20 Sali del glutatione etilestere
DE4220782A1 (de) * 1992-06-25 1994-01-05 Basf Ag Verfahren zur Herstellung von festen pharmazeutischen Retardformen
DE4226753A1 (de) 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
GB9306887D0 (en) 1993-04-01 1993-05-26 Graham Neil B Random block copolymers
WO1995005809A1 (fr) 1993-08-20 1995-03-02 Nippon Shinyaku Co., Ltd. Preparation restant dans l'estomac, forme moulee gonflee, et procede de preparation
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
WO1995014037A1 (en) * 1993-11-17 1995-05-26 Ibah, Inc. Transparent liquid for encapsulated drug delivery
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6787156B1 (en) 1994-02-23 2004-09-07 Bm Research A/S Controlled release composition
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5443178A (en) 1994-06-23 1995-08-22 Allergan, Inc. Tablet dispensing system
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US6113941A (en) 1994-09-30 2000-09-05 Takeda Chemical Industries, Ltd. Substained release microcapsule of physiologically active compound which is slightly water soluble at pH 6 to 8
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE4446470A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von teilbaren Tabletten
DE4446468A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von umhüllten Tabletten
DE4446467A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von linsenförmigen Tabletten durch Schmelzkalandrierung
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
DE19500977C2 (de) 1995-01-14 1999-01-07 Lohmann Therapie Syst Lts Feste Arzneimittelform mit in polymerem Material verteiltem Wirkstoff
NZ270439A (en) 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19509805A1 (de) 1995-03-21 1996-09-26 Basf Ag Transparente, schnell freisetzende Zubereitungen von nichtsteroidalen Analgetica
DE19509806A1 (de) 1995-03-21 1996-09-26 Basf Ag Lagerstabile Arzneiformen
AU706195B2 (en) 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
EP0844870B1 (en) 1995-08-17 2001-11-21 Csir Controlled release products
DE19531277A1 (de) 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
US6391338B1 (en) 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE19536394A1 (de) * 1995-09-29 1997-04-03 Basf Ag Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze
DE19536387A1 (de) 1995-09-29 1997-04-03 Basf Ag Verfahren zur Herstellung von vitaminhaltigen festen Zubereitungen
WO1997013503A1 (en) 1995-10-13 1997-04-17 The Penn State Research Foundation Synthesis of drug nanoparticles by spray drying
DE19539361A1 (de) 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
DE19602206A1 (de) 1996-01-23 1997-07-24 Basf Ag Zubereitungen nichtsteroidaler Analgetika
US5762961A (en) 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5958455A (en) 1996-02-09 1999-09-28 Quadrant Holdings Cambridge Ltd Oral solid dosage forms, methods of making same and compositions thereof
GB2311027B (en) 1996-03-15 1999-10-27 Johnson & Johnson Medical Coated bioabsorbable beads for wound treatment
US20030064108A1 (en) 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
DE19617716A1 (de) 1996-05-03 1997-11-06 Basf Ag In wäßriger Lösung redispergierbare Polymerpulver
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US6764690B2 (en) 1996-05-29 2004-07-20 Delsitech Oy Dissolvable oxides for biological applications
WO1997046222A1 (en) 1996-06-03 1997-12-11 Merck & Co., Inc. Pediatric formulation for hiv protease inhibitors
US5935936A (en) 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
DE19624607A1 (de) 1996-06-20 1998-01-02 Basf Ag Verfahren zur Herstellung von Salzen von Säuregruppen tragenden pharmazeutischen Wirkstoffen
EP2272536B1 (en) 1996-06-26 2016-05-04 Board of Regents, The University of Texas System Hot-melt extrudable Pharmaceutical formulation
DE19629753A1 (de) 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
DE19635676A1 (de) 1996-09-03 1998-03-05 Basf Ag Feste geschäumte Wirkstoffzubereitungen
HRP970485A2 (en) 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
DE19637479A1 (de) 1996-09-13 1998-03-19 Basf Ag Verfahren zur Herstellung fester pharmazeutischer Formen
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
US6071539A (en) 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
US5727878A (en) * 1996-10-17 1998-03-17 Cdf Corporation Liner for a mixing container and an assembly and method for mixing fluid components
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
CN1237902A (zh) 1996-11-15 1999-12-08 默克专利股份公司 制造成形和非成形多元醇材料的方法
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
TW486370B (en) * 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6197787B1 (en) * 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
DE19709663A1 (de) 1997-03-10 1998-09-17 Basf Ag Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten als Bindemittel zur Herstellung von festen pharmazeutischen Darreichungsformen
DE19710009A1 (de) 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
DE19710213A1 (de) 1997-03-12 1998-09-17 Basf Ag Verfahren zur Herstellung von festen Kombinationsarzneiformen
US5948426A (en) 1997-05-03 1999-09-07 Jefferies; Steven R. Method and article to induce hematopoietic expansion
US6610764B1 (en) 1997-05-12 2003-08-26 Metabolix, Inc. Polyhydroxyalkanoate compositions having controlled degradation rates
DE19721467A1 (de) 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US5955475A (en) 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
JPH1125076A (ja) 1997-06-30 1999-01-29 Fujitsu Ltd 文書管理装置および文書管理プログラム記憶媒体
EP0896823B1 (en) * 1997-07-15 2002-09-25 Development Center For Biotechnology Improved stabilization of Misoprostol
DE19733505A1 (de) 1997-08-01 1999-02-04 Knoll Ag Schnell wirksames Analgeticum
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
HN1998000115A (es) 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
ES2236943T3 (es) 1997-09-19 2005-07-16 Shire Laboratories Inc. Perlas de disolucion solida.
JP3460538B2 (ja) 1997-10-08 2003-10-27 救急薬品工業株式会社 速溶性フィルム製剤
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US6547997B1 (en) 1997-11-28 2003-04-15 Abbot Laboratories Method for producing solvent-free noncrystalline biologically active substances
DE19753298A1 (de) * 1997-12-01 1999-06-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
JPH11271927A (ja) * 1998-01-20 1999-10-08 Mitsubishi Paper Mills Ltd 画像材料用支持体
GB9802088D0 (en) 1998-01-30 1998-03-25 Scherer Ltd R P Pharmaceutical products
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
WO1999047124A1 (fr) 1998-03-16 1999-09-23 Yamanouchi Pharmaceutical Co., Ltd. Comprimes a desintegration rapide dans la cavite orale et leur procede de production
DE19812688A1 (de) 1998-03-23 1999-09-30 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE19814730A1 (de) 1998-04-02 1999-10-07 Basf Ag Verwendung von N-Vinyllacram oder N-Vinylamin haltigen Copolymeren als Matrix zur Herstellung von festen pharmazeutischen und kosmetischen Darreichungsformen
US5945123A (en) 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
US20040062802A1 (en) 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
DE19814739A1 (de) 1998-04-02 1999-10-07 Basf Ag Verwendung von Polyalkylenoxid-haltigen Pfropfpolymerisaten als Solubilisatoren
AU763143B2 (en) 1998-04-08 2003-07-17 Kyowa Hakko Kirin Co., Ltd. Tablet manufacturing method and tablet
WO1999055774A1 (en) 1998-04-24 1999-11-04 Eastman Chemical Company Coprecipitation of cellulose esters with functional additives and compositions thus obtainable
JP4027535B2 (ja) 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
WO1999063841A1 (en) 1998-06-05 1999-12-16 Forbes Medi-Tech Inc. Compositions comprising phytosterol and/or phytostanol having enhanced solubility and dispersability
WO1999063971A1 (en) 1998-06-11 1999-12-16 Em Industries, Inc. Micro-osmotic controlled drug delivery systems
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US20010021372A1 (en) 1998-08-18 2001-09-13 Tore Omtveit Apparatus having partially gold-plated surface
DE19839276A1 (de) 1998-08-28 2000-03-02 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE19840256A1 (de) * 1998-09-03 2000-03-09 Basf Ag Verfahren zur Herstellung von beschichteten festen Dosierungsformen
DE19841244A1 (de) 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
DE19842914A1 (de) 1998-09-18 2000-03-23 Basf Ag Testsystem zur Charakterisierung der Verträglichkeit von biologisch aktiven Substanzen und Polyvinylpyrrolidon
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
DE19843904A1 (de) 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit polymerem Bindemittel
US20040013613A1 (en) 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US6383594B2 (en) * 1998-10-07 2002-05-07 Johns Manville International, Inc. Pre-cut fibrous insulation for custom fitting building cavities of different widths
DE19847618A1 (de) 1998-10-15 2000-04-20 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6502135B1 (en) 1998-10-30 2002-12-31 Science Applications International Corporation Agile network protocol for secure communications with assured system availability
DE19853985A1 (de) 1998-11-23 2000-05-25 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
DE19855440A1 (de) 1998-12-01 2000-06-08 Basf Ag Verfahren zum Herstellen fester Darreichungsformen mittels Schmelzextrusion
DE19856147A1 (de) 1998-12-04 2000-06-08 Knoll Ag Teilbare feste Dosierungsformen und Verfahren zu ihrer Herstellung
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
AT407111B (de) 1998-12-22 2000-12-27 Gergely Dr & Co Zucker- und/oder zuckeralkoholhältiges matrixmaterial und verfahren zu seiner herstellung
JP2002534371A (ja) 1999-01-06 2002-10-15 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物
DE19901383A1 (de) 1999-01-15 2000-07-20 Knoll Ag Verfahren zur Herstellung unterschiedlicher fester Dosierungsformen
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
ES2310164T3 (es) 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
US6440946B1 (en) * 1999-02-25 2002-08-27 Takeda Chemical Industries, Ltd. Multiple-agents-binding compound, production and use thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19911097A1 (de) 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
ATE307808T1 (de) * 1999-03-24 2005-11-15 Scherer Technologies Inc R P Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
DE19913606A1 (de) 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE19913692A1 (de) * 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
FR2793689B1 (fr) 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
NL1012300C2 (nl) 1999-06-11 2000-12-12 Rijksuniversiteit Stabilisator voor farmaca.
FR2795326B1 (fr) 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
DE19930454A1 (de) 1999-07-02 2001-01-04 Knoll Ag Feste Paroxetin enthaltende Zubereitungen
DE19934610A1 (de) 1999-07-23 2001-01-25 Bayer Ag Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
SE9903236D0 (sv) 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
DE19943501A1 (de) 1999-09-10 2001-03-15 Basf Ag Unterwassergranulation wirkstoffhaltiger Schmelzen
DK1233755T3 (da) 1999-09-29 2007-10-29 Scherer Technologies Inc R P Hydrolyseret cellulosegranuleringer af salte af lægemidler
DE19949897A1 (de) 1999-10-15 2001-04-19 Rainer Rogasch Formkörper und Verfahren zu dessen Herstellung
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6372259B1 (en) 1999-11-10 2002-04-16 University Of Iowa Research Foundation Palatable, sustained release drug granules
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
PT1227797E (pt) 1999-11-12 2005-05-31 Abbott Lab Formulacoes farmaceuticas de dispersao solida
DE19958007A1 (de) 1999-12-02 2001-06-07 Roehm Gmbh Spritzgußverfahren für (Meth)acrylat-Copolymere mit teritiären Ammoniumgruppen
DE19960494A1 (de) * 1999-12-15 2001-06-21 Knoll Ag Vorrichtung und Verfahren zum Herstellen von festen wirkstoffhaltigen Formen
DE19961334A1 (de) 1999-12-17 2001-06-21 Roehm Gmbh Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere
KR100523127B1 (ko) * 1999-12-23 2005-10-20 화이자 프로덕츠 인코포레이티드 하이드로겔계 약물 투여 형태
HUP0204372A3 (en) * 1999-12-23 2004-06-28 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
EP2415462A1 (en) 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
DE10000792A1 (de) 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
US7029700B2 (en) 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
US6777274B2 (en) * 2000-01-25 2004-08-17 Samsung Electronics Co., Ltd. Low temperature polycrystalline silicon type thin film transistor and a method of the thin film transistor fabrication
GB0003782D0 (en) * 2000-02-17 2000-04-05 Dumex Ltd As Process
GB0005016D0 (en) 2000-03-01 2000-04-26 Jumik Technologies Limited PVA-Containing compositions
DE60119905T2 (de) 2000-03-09 2007-01-11 Ohio State University Research Foundation, Columbus Verfahren zur Herstellung von Feststoffdispersionen
UY26615A1 (es) 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
DE10013289A1 (de) 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
DE10021539C1 (de) 2000-05-03 2002-02-28 Henkel Kgaa Vorrichtung zur Sprühtrocknung von lösungsmittelhaltigen Zusammensetzungen
US20020001617A1 (en) * 2000-05-26 2002-01-03 Chang-Hyun Lee Rapidly disintegrating tablet and process for the manufacture thereof
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE10026699A1 (de) 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
US20100010101A1 (en) * 2000-07-05 2010-01-14 Capricorn Pharma, Inc. Rapid-Melt Compositions and Methods of Making Same
AU2001279284A1 (en) 2000-07-05 2002-01-14 Capricorn Pharma, Inc Rapid-melt semi-solid compositions, methods of making same and methods of using same
IT1318618B1 (it) 2000-07-10 2003-08-27 A C R Applied Coating Res S A Microsfere bioadesive a rilascio rapido per la somministrazionesublinguale di principi attivi.
WO2002005788A1 (en) 2000-07-14 2002-01-24 Universiteit Gent Composite solid shaped articles for the controlled delivery of biologically active ingredients
DE10038571A1 (de) * 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
WO2002013792A1 (fr) 2000-08-11 2002-02-21 Eisai Co., Ltd. Dispersion solide médicamenteuse à solubilité accrue
US6372905B1 (en) * 2000-08-31 2002-04-16 Abbott Laboratories Processes and intermediates for preparing retroviral protease inhibitors
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
FR2814366A1 (fr) * 2000-09-22 2002-03-29 Rhodia Chimie Sa Procede de granulation de matieres actives par extrusion basse pression pour l'obtention de granules directement compressibles
US20040013736A1 (en) * 2000-09-25 2004-01-22 Tomio Nakano Process for producing medicinal solid dispersion
WO2002026372A2 (en) 2000-09-27 2002-04-04 Verion Inc. Instant water dissolvable encapsulate and process
US6579521B2 (en) * 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
WO2002035991A2 (en) 2000-10-30 2002-05-10 The Board Of Regents, The University Of Texas System Spherical particles produced by a hot-melt extrusion/spheronization process
GB0026593D0 (en) * 2000-10-31 2000-12-13 Quadrant Holdings Cambridge Derivatised carbohydrates and their use in solid delivery systems
WO2002038126A2 (en) 2000-11-08 2002-05-16 Aeromatic-Fielder Ag A process for production of particles for pharmaceutical compositions having increased bioavailability
WO2002038184A1 (en) 2000-11-09 2002-05-16 Astrazeneca Ab Oral pharmaceutical composition containing a block copolymer
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
GB0029843D0 (en) 2000-12-07 2001-01-24 Univ Belfast Drug delivery system
US7883721B2 (en) 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US20050175687A1 (en) 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7842308B2 (en) 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
DE60211130T2 (de) 2001-02-13 2006-11-30 Astrazeneca Ab Neue formulierung mit modifizierter freisetzung
GB0104752D0 (en) 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
TWI231211B (en) * 2001-05-01 2005-04-21 Abbott Lab Compositions and methods for enhancing the bioavailability of pharmaceutical agents
ES2231717T3 (es) * 2001-05-03 2005-05-16 F. Hoffmann-La Roche Ag Forma de dosificacion farmaceutica del mesilato de melfinavir amorfo.
AR033711A1 (es) 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
US20030096791A1 (en) 2001-05-31 2003-05-22 Cima Labs Inc. Taste masking of highly water-soluble drugs
DE10127134A1 (de) 2001-06-05 2002-12-12 Roehm Gmbh verfahren zur Herstellung von Formkörpern aus (Meth)acrylat-Copolymeren mittels Spritzguß
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030212102A1 (en) 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
WO2003000294A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
ATE444060T1 (de) 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
NZ529490A (en) 2001-06-22 2005-08-26 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
TNSN03137A1 (en) 2001-06-22 2005-12-23 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
CA2450748A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
ITMI20011337A1 (it) 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
ITMI20011338A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo
ES2739852T3 (es) * 2001-07-06 2020-02-04 Veloxis Pharmaceuticals As Aglomeración controlada
US20030044474A1 (en) 2001-08-03 2003-03-06 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
FR2828380B1 (fr) 2001-08-10 2005-07-29 Fontarome Composition a structure composite contenant des substances aromatiques et/ou des substances non aromatiques volatiles et/ou sensibles aux agents exterieurs, et son procede de fabrication
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
WO2003024426A1 (en) 2001-09-21 2003-03-27 Egalet A/S Controlled release solid dispersions
ATE404179T1 (de) 2001-09-28 2008-08-15 Mcneil Ppc Inc Darreichungsformen mit kern und äusserer hülle
US6982094B2 (en) 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
DE10151290A1 (de) 2001-10-22 2003-04-30 Roehm Gmbh Verfahren zur Herstellung von wirkstoffhaltigen Pellets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005509001A (ja) 2001-10-29 2005-04-07 セリクス， インコーポレイテッド 投薬形態の三次元懸濁液プリンティング
US7491407B2 (en) * 2001-10-31 2009-02-17 North Carolina State University Fiber-based nano drug delivery systems (NDDS)
JP2003146869A (ja) 2001-11-14 2003-05-21 Scg:Kk 口腔内崩壊型固形製剤及びその製造方法
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
WO2003043603A1 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
US7179488B2 (en) * 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC
AU2002219964A1 (en) 2001-11-29 2003-06-17 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20030147965A1 (en) 2001-12-10 2003-08-07 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
NZ533784A (en) 2002-01-03 2006-08-31 Smithkline Beecham Corp Novel pharmaceutical dosage forms and method for producing same
CN1688291A (zh) 2002-02-01 2005-10-26 辉瑞产品公司 含有固体药物分散体的即刻释放剂型
KR100758045B1 (ko) 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
RS61604A (en) 2002-02-01 2006-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
DE10208344A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
CA2478519C (en) 2002-03-07 2011-08-02 Eurand Pharmaceuticals Limited Process for loading and thermodynamically activating drugs on polymers by means of supercritical fluids
DE60222734T2 (de) 2002-03-15 2008-07-17 Alrise Biosystems Gmbh Mikropartikel und Verfahren zur deren Herstellung
DE10213242A1 (de) 2002-03-25 2003-10-16 Abbott Gmbh & Co Kg Testsystem zur Evaluierung der Kompatibilität biologisch aktiver Substanzen mit Copolymeren
DE10213977A1 (de) 2002-03-28 2003-10-16 Krauss Maffei Kunststofftech Verfahren zum Herstellen von Wirkstoffe enthaltenden Formkörpern
EP3241548A1 (en) 2002-04-05 2017-11-08 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
NZ535810A (en) 2002-04-19 2007-11-30 Novartis Ag Biomaterial precipitated from cyclodextrin, an anionic polymer component and an amphiphilic ammonium type compound
US20030203027A1 (en) 2002-04-26 2003-10-30 Ethicon, Inc. Coating technique for deposition of drug substance on a substrate
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
MXPA04011004A (es) * 2002-05-07 2005-01-25 Control Delivery Sys Inc Procesos para formar un dispositivo de administracion de farmaco.
GB0214013D0 (en) 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
EP1515703A1 (en) * 2002-06-21 2005-03-23 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
CN100515388C (zh) * 2002-06-26 2009-07-22 金拓 难溶药物快速溶出固体剂型
AR039744A1 (es) 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
US7155459B2 (en) * 2002-06-28 2006-12-26 Miccrosoft Corporation Time-bound database tuning
US7407670B2 (en) 2002-07-04 2008-08-05 Janssen Pharmaceutica, N.V. Solid dispersions comprising two different polymer matrixes
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
TW200410714A (en) * 2002-08-07 2004-07-01 Smithkline Beecham Corp Electrospun amorphous pharmaceutical compositions
JP2006500349A (ja) 2002-08-12 2006-01-05 ファイザー・プロダクツ・インク 半順序薬剤およびポリマーの医薬組成物
AU2003258209A1 (en) 2002-08-13 2004-02-25 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
CA2494188A1 (en) 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery system including a hydrophobic cellulose derivative
ATE487470T1 (de) * 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
US20040062778A1 (en) 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
DE10247037A1 (de) 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
FR2846557B1 (fr) * 2002-10-30 2007-06-08 Statice Sante Structure implantable pour la liberation prolongee et controlee d'un principe actif
AU2003304108B2 (en) 2002-10-30 2007-03-22 Spherics, Inc. Nanoparticulate bioactive agents
DE10250711A1 (de) 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
CA2510261A1 (en) 2002-12-17 2004-07-01 Abbott Gmbh & Co. Kg Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US6872799B2 (en) 2002-12-18 2005-03-29 Ethicon, Inc. Functionalized polymers for medical applications
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1575563B1 (en) * 2002-12-19 2007-02-14 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
ITMI20022748A1 (it) 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
WO2004062643A1 (en) 2003-01-14 2004-07-29 Lifecycle Pharma A/S Dry dispersions
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
US20040258752A1 (en) 2003-01-31 2004-12-23 Paruthi Manoj Kumar Taste masking pharmaceutical composition and process for its preparation
CN100594023C (zh) 2003-02-03 2010-03-17 诺瓦提斯公司 药物制剂
US20040156894A1 (en) 2003-02-07 2004-08-12 Grother Leon Paul Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
WO2004071494A2 (en) 2003-02-13 2004-08-26 Phares Pharmaceutical Research N.V. Lipophilic compositions
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
US20040185170A1 (en) 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
JP4989217B2 (ja) * 2003-03-26 2012-08-01 エガレット エイ／エス 薬剤物質の送達制御用マトリックス組成物
US20040208928A1 (en) 2003-04-15 2004-10-21 Animal Technology Institute Taiwan Method for preparing an orally administrable formulation for controlled release
CA2523218A1 (en) * 2003-04-22 2004-11-04 Dr. Reddy's Laboratories Limited Oral pharmaceutical formulations of acid-labile active ingredients and process for making same
JP2007516220A (ja) 2003-05-06 2007-06-21 ビーピーエスアイ ホールディングス，インコーポレーテッド アクリルポリマー接着剤を含有する熱成形組成物の製造方法、医薬製剤および該製剤の製造方法
GB0310300D0 (en) 2003-05-06 2003-06-11 Univ Belfast Nanocomposite drug delivery composition
JP2004339162A (ja) 2003-05-16 2004-12-02 Shin Etsu Chem Co Ltd 難溶性薬物を含む医薬用固形製剤とその製造方法
EP1479381A1 (en) 2003-05-19 2004-11-24 Euro-Celtique S.A. Pharmaceutical dosage form comprising a solid solution
MXPA05012821A (es) * 2003-05-28 2006-02-13 Nektar Therapeutics Formulacion farmaceutica que comprende un agente activo insoluble en agua.
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
DE10325989A1 (de) 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
EP1638533A1 (en) 2003-06-18 2006-03-29 John Michael Newton Controlled release devices with lumens
WO2005000237A2 (en) 2003-06-25 2005-01-06 University Of Tennessee Research Foundation Granules containing biologically active substances
CA2531486C (en) 2003-07-11 2012-10-02 Antonio A. Albano Saquinavir mesylate oral dosage form
DE10332160A1 (de) 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
TW200526274A (en) 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
BR0302523A (pt) 2003-07-23 2005-04-05 Cristalia Prod Quimicos Farm Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease
US7785512B1 (en) 2003-07-31 2010-08-31 Advanced Cardiovascular Systems, Inc. Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices
US7645474B1 (en) * 2003-07-31 2010-01-12 Advanced Cardiovascular Systems, Inc. Method and system of purifying polymers for use with implantable medical devices
DE602004017198D1 (de) 2003-08-04 2008-11-27 Camurus Ab Verfahren zum beladen von amphiphilen teilchen mit wirkstoffen
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
WO2005011635A2 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
JP2007501224A (ja) * 2003-08-05 2007-01-25 フジ フォト フィルム ビー．ブイ． 安定剤としての組換え又は合成ゼラチン様タンパク質の、凍結乾燥医薬組成物中の使用
DE10339197A1 (de) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
EP1675576A1 (en) 2003-10-03 2006-07-05 LifeCycle Pharma A/S A method for preparing modified release pharmaceutical compositions
US7598412B2 (en) 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8349361B2 (en) 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
KR101159617B1 (ko) 2003-10-15 2012-06-27 후지카가쿠고교가부시키가이샤 구강내 속붕해성 정제
BRPI0415935A (pt) * 2003-10-27 2007-01-02 Vertex Pharma combinações para tratamento de hcv
US7413690B1 (en) 2003-10-29 2008-08-19 The University Of Mississippi Process and apparatus for producing spherical pellets using molten solid matrices
CA2549539C (en) 2003-12-15 2013-02-12 Council Of Scientific & Industrial Research Taste masked pharmaceutical composition comprising ph sensitive polymer
CA2568378C (en) 2004-05-28 2013-03-19 Abbott Gmbh & Co. Kg Formulation obtained from a powder mixture comprising an inorganic pigment
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
DE102004040104A1 (de) 2004-08-18 2006-02-23 Basf Ag Verwendung von amphiphilen Copolymerisaten als Solubilisatoren
GB0501835D0 (en) 2005-01-28 2005-03-09 Unilever Plc Improvements relating to spray dried compositions
US20090104269A1 (en) 2005-02-11 2009-04-23 Brian Graham Nanoformulations
AU2006218193A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
US20080187612A1 (en) 2005-06-03 2008-08-07 David Kannar Delivery Systems
WO2007002041A2 (en) 2005-06-21 2007-01-04 Foster Corporation Drug-filled polymer films
EP1906940A2 (en) 2005-07-26 2008-04-09 Glaxo Group Limited Encapsulation of lipid-based formulations in enteric polymers
CA2618264C (en) 2005-08-08 2015-11-24 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
CN101283008A (zh) 2005-08-11 2008-10-08 巴斯夫欧洲公司 基于n-乙烯基已内酰胺的共聚物及其作为增溶剂的用途
UA91376C2 (ru) 2005-08-24 2010-07-26 Рубикон Рисеч Пвт Лтд. Рецептура с контролируемым высвобождением
US20070077305A1 (en) 2005-10-03 2007-04-05 Le Tien C Biocompatible polymeric matrix and preparation thereof
WO2007050631A2 (en) 2005-10-25 2007-05-03 Cima Labs Inc. Dosage form with coated active
ITMI20052461A1 (it) * 2005-12-22 2007-06-23 Univ Degli Studi Milano Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive
EP1986591A1 (en) 2006-02-10 2008-11-05 LG Household & Health Care Ltd. In-situ melting and gelling tablet composition for oral care
US20070287664A1 (en) 2006-03-23 2007-12-13 Schering Corporation Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
US7771632B2 (en) 2006-05-15 2010-08-10 American Leistritz Extruder Corp. Continuous melt spheronization apparatus and process for the production of pharmaceutical pellets
EP2029107A2 (de) 2006-06-07 2009-03-04 Basf Se Verwendung von vinylacetat-sulfonat-copolymeren als solubilisatoren für in wasser schwerlösliche verbindungen
US8343548B2 (en) * 2006-08-08 2013-01-01 Shin-Etsu Chemical Co., Ltd. Solid dosage form comprising solid dispersion
US7923026B2 (en) 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
WO2008067164A2 (en) 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
WO2009013202A1 (de) 2007-07-26 2009-01-29 Basf Se Verfahren zur herstellung von durch pfropfpolymerisation in lösung erhaltenen copolymeren auf basis von polyethern in fester form
EP2022805A3 (en) * 2007-08-03 2009-02-25 Basf Se Copolymers based on N-vinyllactams and olefins as their use as solubilizers for slightly water-soluble compounds
MY185300A (en) 2007-10-11 2021-04-30 Philip Morris Products Sa Smokeless tobacco product
CA2718255C (en) * 2008-03-11 2016-08-23 Aska Pharmaceutical Co., Ltd. Solid dispersion and pharmaceutical composition of the same, and production processes thereof
AR071375A1 (es) 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
WO2010017053A1 (en) 2008-08-06 2010-02-11 Isp Investments, Inc. Solid excipient compositions
GB0815852D0 (en) 2008-09-01 2008-10-08 Unilever Plc Improvements relating to pharmaceutical compositions
US20100068268A1 (en) * 2008-09-15 2010-03-18 Miloud Rahmouni Starch-based microparticles for the release of agents disposed therein
US8778401B2 (en) 2008-10-28 2014-07-15 Agency For Science, Technology And Research Mesoporous material excipients for poorly aqueous soluble ingredients
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
WO2010078429A1 (en) 2008-12-30 2010-07-08 Impax Laboratories, Inc. Pharmaceutical dosage forms and methods of manufacturing same
CN101444494B (zh) 2008-12-31 2011-03-30 江苏大学 难溶性药物高效长效缓释制剂及其制法
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2311435A1 (en) 2009-10-07 2011-04-20 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer
WO2011090724A2 (en) 2009-12-29 2011-07-28 Impax Laboratories, Inc. Gastroretentive solid oral dosage forms with lipid-based low-density excipient
EP2552402B1 (en) 2010-03-26 2016-11-23 Dow Global Technologies LLC Multilayer melt-extruded film
US20110288181A1 (en) 2010-05-21 2011-11-24 Basf Se Preparations of biologically active substances with enlarged surface based on amphiphilic copolymers
CN103153343B (zh) 2010-06-14 2015-02-11 陶氏环球技术有限责任公司 具有提高的醋酸酯和琥珀酸酯取代的醋酸羟丙基甲基纤维素琥珀酸酯

Also Published As

Publication number Publication date
EP3482762A1 (en) 2019-05-15
RS57938B1 (sr) 2019-01-31
PT2206500T (pt) 2018-07-04
TR201816268T4 (tr) 2018-11-21
EA014446B1 (ru) 2010-12-30
CY1120377T1 (el) 2019-07-10
PE20100123A1 (es) 2010-03-03
JP2008531565A (ja) 2008-08-14
JP5087409B2 (ja) 2012-12-05
GEP20105083B (en) 2010-09-27
TW200716119A (en) 2007-05-01
CY1122777T1 (el) 2020-10-14
CA2598827A1 (en) 2006-08-31
CA2821046A1 (en) 2006-08-31
MY146247A (en) 2012-07-31
KR20070114294A (ko) 2007-11-30
ES2675548T3 (es) 2018-07-11
NO20074807L (no) 2007-09-21
HRP20180999T1 (hr) 2018-08-10
WO2006091529A2 (en) 2006-08-31
CA2598827C (en) 2013-09-24
SI2283844T1 (sl) 2018-12-31
EP2206500A1 (en) 2010-07-14
PE20061016A1 (es) 2006-10-03
CL2017001847A1 (es) 2018-04-27
SI2206500T1 (en) 2018-08-31
CN101163479B (zh) 2011-12-07
DOP2006000050A (es) 2006-11-15
BR122012031169A2 (pt) 2015-07-07
MX2007010275A (es) 2007-11-08
DK2206500T3 (en) 2018-07-16
HUE038073T2 (hu) 2018-09-28
AR055734A1 (es) 2007-09-05
CR9353A (es) 2008-03-18
CN101163479A (zh) 2008-04-16
AR077411A2 (es) 2011-08-24
IL185390A (en) 2017-06-29
DK2283844T3 (en) 2018-11-26
CL2009001844A1 (es) 2009-12-11
WO2006091529A3 (en) 2007-02-08
EP1855683A2 (en) 2007-11-21
BRPI0609173A2 (pt) 2010-02-23
ES2694073T3 (es) 2018-12-17
TR201809084T4 (tr) 2018-07-23
PL2206500T3 (pl) 2018-09-28
UY32116A (es) 2011-04-29
RS57378B1 (sr) 2018-08-31
ZA200707022B (en) 2009-08-26
US20080299203A1 (en) 2008-12-04
LT2283844T (lt) 2018-11-12
US20050143404A1 (en) 2005-06-30
US20130004578A1 (en) 2013-01-03
AU2006216856A1 (en) 2006-08-31
SV2007002427A (es) 2007-01-08
NZ599361A (en) 2013-10-25
KR101429024B1 (ko) 2014-08-12
EP2283844B1 (en) 2018-08-01
CL2013003554A1 (es) 2014-05-09
DOP2019000185A (es) 2019-08-15
HRP20181819T1 (hr) 2019-01-11
GT200600295AA (es) 2012-03-12
US8377952B2 (en) 2013-02-19
PT2283844T (pt) 2018-11-16
EP2206500B1 (en) 2018-03-28
LT2206500T (lt) 2018-07-10
AU2006216856B2 (en) 2012-03-08
TWI381840B (zh) 2013-01-11
HUE041591T2 (hu) 2019-05-28
NZ560829A (en) 2010-12-24
UA89220C2 (ru) 2010-01-11
CA2821046C (en) 2018-04-24
UY29391A1 (es) 2006-10-02
EP2283844A1 (en) 2011-02-16
EA200701790A1 (ru) 2008-02-28
IL185390A0 (en) 2008-02-09
GT200600295A (es) 2007-09-13

Similar Documents

Publication Publication Date Title
HRP20181819T1 (hr) Formulacija krutog farmaceutskog oblika doziranja koja sadrži lopinavir
IL251539A0 (en) Single pharmaceutical dosage form
TWI366460B (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
ME01550B (me) Farmaceutski dozni oblici
EP1898922A4 (en) MEDICINE OR IMPROVED PHARMACEUTICAL COMPOUNDS AND PREPARATION THEREOF
IL191531A0 (en) Orally absorbed pharmaceutical formulation
IL180706A0 (en) Pharmaceutical dosage forms including rasagiline
EP2112925A4 (en) SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
HK1198914A1 (en) Novel dosage formulation
ZA200709788B (en) Cannabinold active pharmaceutical ingredient for Improved dosage forms
ZA200803152B (en) Oramucosal pharmaceutical dosage form
EP1948138A4 (en) SEGMENTED PHARMACEUTICAL FORMS
HK1105358A1 (en) Solid pharmaceutical formulation
IL189827A0 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
GB0522473D0 (en) A pharmaceutical formulation
GB0515937D0 (en) Pharmaceutical formulation
GB0422111D0 (en) Pharmaceutical formulation
GB0418270D0 (en) Pharmaceutical formulation
GB0417042D0 (en) Stable pharmaceutical formulation